Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.
Mesothelin is a cell surface associated antigen expressed on mesothelial cells and in some malignant neoplasms. Mesothelin-targeted therapies are in phase I/II clinical trials. The clinicopathologic and prognostic significance of mesothelin expression in triple negative breast carcinomas (TNBC) has...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4266616?pdf=render |
id |
doaj-16728cc824874c4888ec9ca43a83632a |
---|---|
record_format |
Article |
spelling |
doaj-16728cc824874c4888ec9ca43a83632a2020-11-25T01:27:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01912e11490010.1371/journal.pone.0114900Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.Gary TozbikianEdi BrogiKyuichi KadotaJeffrey CatalanoMuzaffar AkramSujata PatilAlice Y HoJorge S Reis-FilhoBritta WeigeltLarry NortonPrasad S AdusumilliHannah Yong WenMesothelin is a cell surface associated antigen expressed on mesothelial cells and in some malignant neoplasms. Mesothelin-targeted therapies are in phase I/II clinical trials. The clinicopathologic and prognostic significance of mesothelin expression in triple negative breast carcinomas (TNBC) has not been fully assessed. We evaluated the expression of mesothelin and of basal markers in tissue microarrays of 226 TNBC and 88 non-TNBC and assessed the clinicopathologic features of mesothelin-expressing breast carcinomas. Furthermore, we investigated the impact of mesothelin expression on the disease-free and overall survival of patients with TNBC. We found that mesothelin expression is significantly more frequent in TNBC than in non-TNBC (36% vs 16%, respectively; p = 0.0006), and is significantly correlated with immunoreactivity for basal keratins, but not for EGFR. Mesothelin-positive and mesothelin-negative TNBC were not significantly different by patients' race, tumor size, histologic grade, tumor subtype, lymphovascular invasion and lymph node metastases. Patients with mesothelin-positive TNBC were older than patients with mesothelin-negative TNBC, developed more distant metastases with a shorter interval, and had significantly lower overall and disease-free survival. Based on our results, patients with mesothelin-positive TNBC could benefit from mesothelin-targeted therapies.http://europepmc.org/articles/PMC4266616?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gary Tozbikian Edi Brogi Kyuichi Kadota Jeffrey Catalano Muzaffar Akram Sujata Patil Alice Y Ho Jorge S Reis-Filho Britta Weigelt Larry Norton Prasad S Adusumilli Hannah Yong Wen |
spellingShingle |
Gary Tozbikian Edi Brogi Kyuichi Kadota Jeffrey Catalano Muzaffar Akram Sujata Patil Alice Y Ho Jorge S Reis-Filho Britta Weigelt Larry Norton Prasad S Adusumilli Hannah Yong Wen Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS ONE |
author_facet |
Gary Tozbikian Edi Brogi Kyuichi Kadota Jeffrey Catalano Muzaffar Akram Sujata Patil Alice Y Ho Jorge S Reis-Filho Britta Weigelt Larry Norton Prasad S Adusumilli Hannah Yong Wen |
author_sort |
Gary Tozbikian |
title |
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. |
title_short |
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. |
title_full |
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. |
title_fullStr |
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. |
title_full_unstemmed |
Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. |
title_sort |
mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Mesothelin is a cell surface associated antigen expressed on mesothelial cells and in some malignant neoplasms. Mesothelin-targeted therapies are in phase I/II clinical trials. The clinicopathologic and prognostic significance of mesothelin expression in triple negative breast carcinomas (TNBC) has not been fully assessed. We evaluated the expression of mesothelin and of basal markers in tissue microarrays of 226 TNBC and 88 non-TNBC and assessed the clinicopathologic features of mesothelin-expressing breast carcinomas. Furthermore, we investigated the impact of mesothelin expression on the disease-free and overall survival of patients with TNBC. We found that mesothelin expression is significantly more frequent in TNBC than in non-TNBC (36% vs 16%, respectively; p = 0.0006), and is significantly correlated with immunoreactivity for basal keratins, but not for EGFR. Mesothelin-positive and mesothelin-negative TNBC were not significantly different by patients' race, tumor size, histologic grade, tumor subtype, lymphovascular invasion and lymph node metastases. Patients with mesothelin-positive TNBC were older than patients with mesothelin-negative TNBC, developed more distant metastases with a shorter interval, and had significantly lower overall and disease-free survival. Based on our results, patients with mesothelin-positive TNBC could benefit from mesothelin-targeted therapies. |
url |
http://europepmc.org/articles/PMC4266616?pdf=render |
work_keys_str_mv |
AT garytozbikian mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT edibrogi mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT kyuichikadota mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT jeffreycatalano mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT muzaffarakram mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT sujatapatil mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT aliceyho mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT jorgesreisfilho mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT brittaweigelt mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT larrynorton mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT prasadsadusumilli mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival AT hannahyongwen mesothelinexpressionintriplenegativebreastcarcinomascorrelatessignificantlywithbasallikephenotypedistantmetastasesanddecreasedsurvival |
_version_ |
1725104577303281664 |